An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial

PURPOSE: To evaluate the ocular hyperemia and intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.01% in subjects with elevated IOP due to primary open-angle glaucoma (POAG) or ocular hypertension (OHT) in a real-world clinical setting. SUBJECTS AND METHODS: This open-label, 12-week, obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Crichton, Andrew C, Nixon, Donald R, Simonyi, Susan, Bhogal, Meetu, Sigouin, Christopher S, Discepola, Marino J, Hutnik, Cindy ML, Baptiste, Darryl C, Yan, David B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043802/
https://www.ncbi.nlm.nih.gov/pubmed/24920879
http://dx.doi.org/10.2147/OPTH.S46298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043802/
https://www.ncbi.nlm.nih.gov/pubmed/24920879
http://dx.doi.org/10.2147/OPTH.S46298

Ejemplares similares